M&A Deal Summary

AstraZeneca Acquires Fusion Pharmaceuticals

On March 19, 2024, AstraZeneca acquired life science company Fusion Pharmaceuticals for 2.4B USD

Acquisition Highlights
  • This is AstraZeneca’s 17th transaction in the Life Science sector.
  • This is AstraZeneca’s 6th largest (disclosed) transaction.
  • This is AstraZeneca’s 2nd transaction in Canada.
  • This is AstraZeneca’s 1st transaction in Ontario.

M&A Deal Summary
Date 2024-03-19
Target Fusion Pharmaceuticals
Sector Life Science
Buyer(s) AstraZeneca
Deal Type Add-on Acquisition
Deal Value 2.4B USD

Target

Fusion Pharmaceuticals

Hamilton, Ontario, Canada
Fusion Pharmaceuticals is a pharmaceutical company focused on the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. Fusion Pharmaceuticals was formed in 2014 and is based in Hamilton, Ontario.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AstraZeneca

Cambridge, United Kingdom
Category Company
Founded 1992
Sector Life Science
Employees83,100
Revenue 45.8B USD (2023)
DESCRIPTION
Main office on AstraZeneca's campus in Waltham, Massachusetts.
Main office on AstraZeneca's campus in Waltham, Massachusetts.

AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The Company's aim is to improve the health and quality of life of patients around the world through medicines, treatment solutions, and accessibility to healthcare. AstraZeneca is involved in both the research and development (R&D) and manufacturing of drugs to address critical areas of unmet medical need. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.

DEAL STATS #
Overall 19 of 19
Sector (Life Science) 17 of 17
Type (Add-on Acquisition) 15 of 15
State (Ontario) 1 of 1
Country (Canada) 2 of 2
Year (2024) 2 of 2
Size (of disclosed) 6 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-03-14 Amolyt Pharma

Ecully, France

Amolyt Pharma is a clinical-stage biotechnology company, building therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma was founded in 2015 and is based in Ecully, France.

Buy $1.1B
Mergr

Product

Company

Legal